Trial Profile
Endostatin in combination with docetaxel for patients with NSCLC who resistant to the prior EGFR-TKI agent treatment.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 24 May 2012
Price :
$35
*
At a glance
- Drugs Endostatin (Primary) ; Docetaxel
- Indications Non-small cell lung cancer
- Focus Adverse reactions; Therapeutic Use
- Acronyms EnDOC
- 21 May 2012 Actual end date (Dec 2010) added as reported by Chinese Clinical Trial Register record.
- 24 Jan 2012 Status changed from recruiting to completed as reported by Chinese Clinical Trial Register record (ChiCTR-ONC09000355).
- 29 Dec 2011 Additional trial acronym (EnDOC) identified as reported by Chinese Clinical Trial Register record.